CMS Call on the Treatment of Alzheimer’s Disease w/ Monoclonal Antibodies Directed Against Amyloid

On May 11, 2022, the Centers for Medicare & Medicaid Services hosted a listening session for stakeholders on the final national coverage determination of the treatment of Alzheimer’s disease with monoclonal antibodies directed against amyloid, and to provide an opportunity for stakeholders to provide feedback and ask clarifying questions.